Japanese Pharmacokinetic Bridging Study for CC-93538

Phase 1

Completed

• Conditions: Healthy Volunteers
• Interventions: Drug: CC-93538

• Registration Number: NCT04096105
• Lead Sponsor: Celgene

Brief Summary

This is an open-label, randomized, parallel design study to evaluate the PK, safety, tolerability and immunogenicity of single SC doses of CC-93538 in healthy Japanese and Caucasian adult subjects.

A total of approximately 48 subjects, 24 Japanese and 24 Caucasians, will be enrolled. Japanese subjects will be enrolled first and randomized 1:1 to receive a single SC dose of either 180 mg or 360 mg CC-93538. Caucasian subjects will then be enrolled and matched to Japanese subjects (1:1) by weight (± 20%) and receive the same single SC dose of either 180 mg or 360 mg CC-93538.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-09-04
• Study First Submitted QC: 2019-09-18
• Study First Posted: 2019-09-19
• Study Start: 2019-10-14
• Primary Completion: 2020-01-29
• Study Completion: 2020-01-30
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-20
• Last Update Posted: 2020-08-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject must be male or non-pregnant female, aged ≥ 18 and ≤ 55 years of age at the time of signing the ICF.

2. Subject must have a body weight of at least 40 kg; a BMI ≥18 and ≤ 30 kg/m2 at screening. Japanese and Caucasian subjects will be matched by body weight (± 20%).

3. Japanese subjects must have been born in Japan and not have lived outside of Japan > 5 years, have both parents and grandparents of Japanese origin, and have not significantly modified their diets since leaving Japan.

4. Caucasian subjects must be of European or Latin American descent (ie, White).

5. Subject must be in good health, as determined by the Investigator on the basis of medical history, clinical laboratory safety test results, vital signs, 12-lead ECG, and PE at screening.

6. Female subjects not of childbearing potential must:

   1. Have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before Screening, or
   2. Postmenopausal (defined as 24 consecutive months without menses before Screening, with a follicle stimulating hormone [FSH] level in the postmenopausal range according to the laboratory used at Screening); FSH to be performed at the discretion of the Investigator in consultation with the Medical Monitor.

7. Females of child-bearing potential (FCBP) must agree to practice a highly effective method of contraception throughout the study and for 5 months after the last dose of investigational product (IP). Acceptable methods of birth control in this study are the following:

   • Combined hormonal (containing oestrogen and progestogen) contraception, which may be oral, intravaginal, or transdermal
   • Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable or implantable
   • Placement of an intrauterine device or intrauterine hormone-releasing system
   • Bilateral tubal occlusion
   • Vasectomised partner
   • Sexual abstinence

8. Male subjects must:

   1. Practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to use a latex condom during sexual contact with FCBP while participating in the study until 5 months after the last dose of IP.
   2. Agree to refrain from donating sperm during the study until 5 months after the last dose of IP.

   Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

9. Subjects must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted, and must be able to comply with the requirements of the study, including the study visit schedule and other protocol requirements. Must be able to communicate with the Investigator and

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment:

1. Subject has any significant medical history/condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
3. Subject has any condition that confounds the ability to interpret data from the study.
4. Subject was exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever was longer).
5. Subject has a history of infection within 30 days of dosing on Day 1.
6. Subject has a history of drug or alcohol abuse (as defined by the investigator), or addiction within 6 months prior to Screening.
7. Subject has used any tobacco- or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, electronic cigarettes, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 3 months prior to Day 1 and during the study.
8. Subject has a positive urine drug test including cotinine, or positive alcohol urine or breath test at Screening or on Day -1.
9. Subject has donated greater than 400 mL of blood within 60 days prior to Day 1.
10. Subject has a positive serum test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
11. Subject has a history of clinically significant allergic reaction to any drug, biologic, food, or vaccine.
12. Subject has a history of major immunologic reaction (such as anaphylactic reaction, anaphylactoid reaction, or serum sickness) to any IgG-containing agent.
13. Subject fails or is unwilling to abstain from strenuous physical activities for at least 24 hours prior to dosing (Day 1) and throughout the study
14. Subject has tattoos (> 25% of their body) or other skin markings (eg, scars) that, in the opinion of the investigator, would prevent visualization of dermatologic changes due to study treatment
15. Subject has been diagnosed with or is being treated for a parasitic/helminthic infection or subject has systemic or diarrheal illness following travel or residence in endemic areas of parasitic/helminthic infections, history of clinical schistosomiasis, and history of travel to endemic areas within preceding 6 months.
16. Subject has a history of tuberculosis, listeriosis, or untreated parasitic infections.
17. Subject has a history of hereditary fructose intolerance.
18. Subject is, for any reason, deemed by the Investigator to be inappropriate for this study.
19. Subject has received any drug by injection within 30 days of Day 1.
20. Subject has poor peripheral venous access.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Administration of CC-93538 in Caucasian subjects	CC-93538	Twenty-four Caucasian subjects will be matched to Japanese subjects by weight (± 20%) and receive a 180 mg or 360 mg dose via SC injection
CC-93538 in Japanese subjects	CC-93538	Twenty-four Japanese subjects will be randomized into 1 of 2 dose levels in a 1:1 fashion so that 12 subjects will receive a 180 mg or 360 mg dose via SC injection.

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics - CL/F	from pre-dose to up to Day 70	Apparent clearance of drug from serum after extravascular administration
Pharmacokinetics - tmax	from pre-dose to up to Day 70	Time to Cmax
Pharmacokinetics - Cmax	from pre-dose to up to Day 70	Maximum observed concentration of drug
Pharmacokinetics - Vz/F	from pre-dose to up to Day 70	Apparent volume of distribution during the terminal phase
Pharmacokinetics - AUC0-last	from pre-dose to up to Day 70	Area under the concentration-time curve calculated from time zero to the last measured concentration
Pharmacokinetics - AUC0-∞	from pre-dose to up to Day 70	Area under the concentration-time curve calculated from time zero to infinity
Pharmacokinetics - t½	from pre-dose to up to Day 70	Terminal elimination half-life

Secondary Outcome Measures

Name	Time	Method
Adverse Events (AEs)	From the time the informed consent form (ICF) is signed and until 70 days after the last dose of CC-93538	Number participants with adverse event
Immunogenicity profile for CC-93538	from pre-dose to up to Day 70	Positive or negative for the presence of antidrug antibodies against CC-93538 in blood

Trial Locations

Locations (1)

Anaheim Clinical Trials; 🇺🇸 Anaheim, California, United States